Dr. Shen Huaqiong from Tianjing Biotech will leave his post. Exclusive reply: I hope to return to our business——CNS drug development

Yesterday, news broke that the current CEO Dr.

It is reported that after Dr.

After the news broke, Sina Medicine immediately confirmed the news to Dr.

At the end of 2016, Sina Pharmaceuticals had an in-depth interview with Dr.

It is reported that Dr.

In 2003, he was hired as a clinical research physician by the R&D department of Eli Lilly, a US pharmaceutical company, to engage in clinical research on psychiatric drugs

In 2005, he joined Wyeth as the medical director, responsible for the global development strategy and clinical plan of the compound

In 2009, he became the senior director of Pfizer Pharmaceuticals.

Joined Shanghai Hengrui Pharmaceutical Co.

Joined China Johnson & Johnson in 2015 and served as General Manager and Vice President of China Development Center of Johnson & Johnson Pharmaceuticals

In September 2017, he joined Tianjing Biotech as the president and director of R&D, and was later promoted to chief executive officer

In December 2021, the news broke that Dr.

At the time when the news of Dr.

Dr.

Prior to this, Tianjing Biological also announced two important executive appointments:

Appointed Mr.

The former CFO Mr.

Tianjing Bio was established in 2016.
In recent years, it has achieved a number of innovations.
For example, it has developed innovative products such as the CD47 antibody Lezolizumab, the CD73 antibody Ulelimumab, and the GM-CSF antibody Pranalizumab.

.

In September 2020, Tianjing Biotechnology and AbbVie reached a strategic cooperation of nearly US$3 billion with Zolizumab (TJC4) for the CD47 monoclonal antibody, which broke the record of overseas authorized transactions by Chinese biopharmaceutical companies
.

In November 2021, Tianjing Biotechnology and Jichuan Pharmaceutical reached a strategic cooperation of more than 2 billion yuan on Yitan growth hormone, creating a new high in the Chinese biomedical market and in the entire field
.

In January 2020, Tianjing Biotech was officially listed on NASDAQ, the stock code is IMAB, and the listing price is 14 US dollars per share
.

According to the prospectus of Tianjing Bio, one month after Shen Huaqiong joined Tianjing Bio, the company granted him 1,505,128 common stocks with an exercise price of US$1 per US share and an expiry date of 2027/10/1
.

After the listing, the stock price of Tianjing Biological has risen all the way.
By the end of June 2021, the share price of Tianjing Biological has risen to the highest point of 85.
4 US dollars per share, and then began to decline all the way.
As of today (December 21, 2021), the price of Tianjing Biological is 47.
06.
USD/share
.